Study to evaluate antibody response to an additional dose of COVID-19 vaccination with and without immunosuppression reduction in kidney and liver transplant recipients.

Brief description of study

The purpose of the study is to find out whether an extra dose of COVID-19 study dose of vaccine will help to protect people who have had a liver or kidney transplant from COVID-19 by causing their body to make antibodies against the virus that causes COVID-19. Many transplant recipients do not make antibodies after receiving 2 doses of the COVID-19 vaccine. This means that they are more likely to get infected with COVID-19. This study will help us learn whether an additional dose of COVID-19 study vaccine with or without lowering an anti-rejection medicine can help transplant recipients make more antibody to COVID-19.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Kidney,Liver,COVID-19
Age: Between 18 Years - 99 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 850518

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).